Genomic Biomarker Market Report 2025

This genomic biomarker market report delivers an in-depth analysis of the market’s key characteristics, including size, growth potential, and segmentation. It provides a detailed breakdown of the market across major regions and leading countries, highlighting historical data and future growth projections. The report also examines the competitive landscape, market share insights, emerging trends, and strategic developments shaping the market.

The genomic biomarker market size has grown rapidly in recent years. It will grow from $8.4 billion in 2024 to $9.9 billion in 2025 at a compound annual growth rate (CAGR) of 18%. The growth in the historic period can be attributed to growth in awareness of genetic disorders, rise in demand for targeted therapies, increasing utilization of big data in genomics, growth in global genomic databases, and rise in number of biomarker-based clinical trials.

The genomic biomarker market size is expected to see rapid growth in the next few years. It will grow to $18.93 billion in 2029 at a compound annual growth rate (CAGR) of 17.6%. The growth in the forecast period can be attributed to growing focus on the availability of personalized medications, rising occurrences of cardiovascular diseases, rising number of patients with neurological diseases, growing investments in genomic research, and growing adoption of personalized nutrition. Major trends in the forecast period include technological advancements, digital health, artificial intelligence, machine learning, and personalized medicine.

The rising prevalence of chronic diseases is anticipated to drive the growth of the genomic biomarker market. Chronic diseases are long-term health conditions that develop gradually and persist over time. This increase in chronic diseases is attributed to aging populations and the growing incidence of lifestyle-related conditions such as obesity and diabetes. Genomic biomarkers facilitate early detection and personalized prevention strategies by identifying genetic predispositions and customizing interventions. This proactive approach aims to reduce prevalence by targeting at-risk individuals before the onset of disease. For example, in September 2023, the World Health Organization (WHO) reported that chronic diseases account for 74% of all global fatalities, with 41 million deaths annually. This includes 17.9 million deaths from cardiovascular diseases, 9.3 million from cancer, 4.1 million from chronic respiratory diseases, and 2 million from diabetes. Consequently, the rising prevalence of chronic diseases is driving the growth of genomic biomarkers.

Leading companies in the genomic biomarker market are concentrating on developing advanced products, such as sophisticated liquid biopsy assays, to facilitate comprehensive genomic profiling of solid tumors. A liquid biopsy assay is a diagnostic test that examines genetic material, usually circulating tumor DNA (ctDNA), from a blood sample to detect and monitor cancer. Identifying genomic biomarkers provides insights into specific mutations, gene expression profiles, or other genetic changes associated with cancer. For example, in November 2023, Illumina Inc., a US-based biotechnology company, introduced an advanced liquid biopsy assay, the TruSight Oncology 500 ctDNA v2 (TSO 500 ctDNA v2), for thorough genomic profiling of solid tumors. This assay offers improved analytical sensitivity by detecting low-frequency variants with only 20 ng of cell-free DNA, reduced from 30 ng. It provides results in under four days, significantly accelerating genomic profiling compared to traditional methods. The streamlined workflow and upcoming automation will ease lab integration and enhance efficiency.

In November 2022, Biocare Medical LLC, a US-based provider of immunohistochemistry and FISH instrumentation and reagents, acquired Empire Genomics for an undisclosed amount. This acquisition is intended to substantially boost Biocare Medical LLC's molecular diagnostics capabilities and broaden its range of cancer research tools. Empire Genomics, a US-based company specializing in cancer molecular diagnostics, offers genomic biomarkers.

Major companies operating in the genomic biomarker market are Pfizer Inc., Roche Diagnostics, Thermo Fisher Scientific Inc., Merck KGaA, Eurofins Scientific SE, Agilent Technologies Inc., Illumina Inc., PerkinElmer Inc., Beckman Coulter Inc., Bio-Rad Laboratories Inc., Foundation Medicine Inc., QIAGEN N.V., Almac Group Ltd., Myriad Genetics Inc., Invitae Inc., Guardant Health Inc., Novogene Inc., Twist Bioscience Corp., NanoString Technologies Inc., Quanterix Corp., Personalis Inc., GENEWIZ Inc., Agena Bioscience Inc., Creative Diagnostics Ltd., OncoDNA SA, Genome Life Sciences Ltd., Epigenomics AG.

North America was the largest region in the genomic biomarker market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the genomic biomarker market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the genomic biomarker market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

A genomic biomarker is a specific genetic sequence or molecular trait within an individual's genome that helps assess disease risk, predict disease progression, or gauge response to a particular treatment. These biomarkers play a crucial role in personalized medicine, enabling the customization of treatments based on an individual's genetic profile.

The primary types of genomic biomarkers are predictive biomarkers and prognostic biomarkers. Predictive biomarkers are used to determine the likelihood of a patient responding to a specific treatment or drug. They are applicable to a range of diseases, including oncology, cardiovascular conditions, neurological disorders, renal issues, and more. Predictive biomarkers provide analytical validation, clinical validation, and clinical utility. They are utilized by various end users, including hospitals, diagnostic centers, research laboratories, and other institutions.

The genomic biomarker market research report is one of a series of new reports that provides genomic biomarker market statistics, including genomic biomarker industry global market size, regional shares, competitors with a genomic biomarker market share, detailed genomic biomarker market segments, market trends and opportunities, and any further data you may need to thrive in the genomic biomarker industry. This genomic biomarker market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The genomic biomarker market consists of sales of genetic testing kits, genotyping arrays, pharmacogenomic panels and cancer genomics panels. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.